| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 21 |
| 1 | CAPECITABINE | 19 |
| 2 | DOCETAXEL | 18 |
| 3 | DOCETAXEL ANHYDROUS | 18 |
| 4 | BEVACIZUMAB | 16 |
| 5 | ATEZOLIZUMAB | 15 |
| 6 | OXALIPLATIN | 12 |
| 7 | PEMBROLIZUMAB | 12 |
| 8 | LENVATINIB | 7 |
| 9 | CARBOPLATIN | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PENPULIMAB | 1 | 0.0102 |
| 1 | PLATINUM | 1 | 0.0019 |
| 2 | FRUQUINTINIB | 2 | 0.0005 |
| 3 | ATEZOLIZUMAB | 15 | 0.0004 |
| 4 | REGORAFENIB | 4 | 0.0003 |
| 5 | CISPLATIN | 21 | 0.0003 |
| 6 | DOCETAXEL | 18 | 0.0003 |
| 7 | DOCETAXEL ANHYDROUS | 18 | 0.0003 |
| 8 | SORAFENIB | 5 | 0.0002 |
| 9 | LENVATINIB | 7 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 19 | 0.0002 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 3 | Microtubule Inhibitor [EPC] | 22 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 36 | 0.0001 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 16 | 0.0001 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 23 | 0.0001 |
| 7 | Epidermal Growth Factor Receptor Antagonist [EPC] | 2 | 0.0000 |
| 8 | HER2/neu Receptor Antagonist [EPC] | 3 | 0.0000 |
| 9 | Topoisomerase Inhibitor [EPC] | 2 | 0.0000 |